Ligand-directed functional selectivity at the Mu opioid receptor revealed by label-free integrative pharmacology on-target

Megan Morse, Elizabeth Tran, Haiyan Sun, Robert Levenson, Ye Fang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Development of new opioid drugs that provide analgesia without producing dependence is important for pain treatment. Opioid agonist drugs exert their analgesia effects primarily by acting at the mu opioid receptor (MOR) sites. High-resolution differentiation of opioid ligands is crucial for the development of new lead drug candidates with better tolerance profiles. Here, we use a label-free integrative pharmacology on-target (iPOT) approach to characterize the functional selectivity of a library of known opioid ligands for the MOR. This approach is based on the ability to detect dynamic mass redistribution (DMR) arising from the activation of the MOR in living cells. DMR assays were performed in HEK-MOR cells with and without preconditioning with probe molecules using label-free resonant waveguide grating biosensors, wherein the probe molecules were used to modify the activity of specific signaling proteins downstream the MOR. DMR signals obtained were then translated into high resolution heat maps using similarity analysis based on a numerical matrix of DMR parameters. Our data indicate that the iPOT approach clearly differentiates functional selectivity for distinct MOR signaling pathways among different opioid ligands, thus opening new avenues to discover and quantify the functional selectivity of currently used and novel opioid receptor drugs.

Original languageEnglish (US)
Article numbere25643
JournalPloS one
Volume6
Issue number10
DOIs
StatePublished - Oct 7 2011

Fingerprint

mu Opioid Receptor
narcotics
pharmacology
Labels
Opioid Analgesics
Pharmacology
Ligands
receptors
Pharmaceutical Preparations
Analgesia
drugs
Molecules
Aptitude
Opioid Receptors
Biosensing Techniques
analgesia
Biosensors
Libraries
ligands
Assays

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

@article{a532c90b20ec42a393520a836f4a24ef,
title = "Ligand-directed functional selectivity at the Mu opioid receptor revealed by label-free integrative pharmacology on-target",
abstract = "Development of new opioid drugs that provide analgesia without producing dependence is important for pain treatment. Opioid agonist drugs exert their analgesia effects primarily by acting at the mu opioid receptor (MOR) sites. High-resolution differentiation of opioid ligands is crucial for the development of new lead drug candidates with better tolerance profiles. Here, we use a label-free integrative pharmacology on-target (iPOT) approach to characterize the functional selectivity of a library of known opioid ligands for the MOR. This approach is based on the ability to detect dynamic mass redistribution (DMR) arising from the activation of the MOR in living cells. DMR assays were performed in HEK-MOR cells with and without preconditioning with probe molecules using label-free resonant waveguide grating biosensors, wherein the probe molecules were used to modify the activity of specific signaling proteins downstream the MOR. DMR signals obtained were then translated into high resolution heat maps using similarity analysis based on a numerical matrix of DMR parameters. Our data indicate that the iPOT approach clearly differentiates functional selectivity for distinct MOR signaling pathways among different opioid ligands, thus opening new avenues to discover and quantify the functional selectivity of currently used and novel opioid receptor drugs.",
author = "Megan Morse and Elizabeth Tran and Haiyan Sun and Robert Levenson and Ye Fang",
year = "2011",
month = "10",
day = "7",
doi = "10.1371/journal.pone.0025643",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

Ligand-directed functional selectivity at the Mu opioid receptor revealed by label-free integrative pharmacology on-target. / Morse, Megan; Tran, Elizabeth; Sun, Haiyan; Levenson, Robert; Fang, Ye.

In: PloS one, Vol. 6, No. 10, e25643, 07.10.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ligand-directed functional selectivity at the Mu opioid receptor revealed by label-free integrative pharmacology on-target

AU - Morse, Megan

AU - Tran, Elizabeth

AU - Sun, Haiyan

AU - Levenson, Robert

AU - Fang, Ye

PY - 2011/10/7

Y1 - 2011/10/7

N2 - Development of new opioid drugs that provide analgesia without producing dependence is important for pain treatment. Opioid agonist drugs exert their analgesia effects primarily by acting at the mu opioid receptor (MOR) sites. High-resolution differentiation of opioid ligands is crucial for the development of new lead drug candidates with better tolerance profiles. Here, we use a label-free integrative pharmacology on-target (iPOT) approach to characterize the functional selectivity of a library of known opioid ligands for the MOR. This approach is based on the ability to detect dynamic mass redistribution (DMR) arising from the activation of the MOR in living cells. DMR assays were performed in HEK-MOR cells with and without preconditioning with probe molecules using label-free resonant waveguide grating biosensors, wherein the probe molecules were used to modify the activity of specific signaling proteins downstream the MOR. DMR signals obtained were then translated into high resolution heat maps using similarity analysis based on a numerical matrix of DMR parameters. Our data indicate that the iPOT approach clearly differentiates functional selectivity for distinct MOR signaling pathways among different opioid ligands, thus opening new avenues to discover and quantify the functional selectivity of currently used and novel opioid receptor drugs.

AB - Development of new opioid drugs that provide analgesia without producing dependence is important for pain treatment. Opioid agonist drugs exert their analgesia effects primarily by acting at the mu opioid receptor (MOR) sites. High-resolution differentiation of opioid ligands is crucial for the development of new lead drug candidates with better tolerance profiles. Here, we use a label-free integrative pharmacology on-target (iPOT) approach to characterize the functional selectivity of a library of known opioid ligands for the MOR. This approach is based on the ability to detect dynamic mass redistribution (DMR) arising from the activation of the MOR in living cells. DMR assays were performed in HEK-MOR cells with and without preconditioning with probe molecules using label-free resonant waveguide grating biosensors, wherein the probe molecules were used to modify the activity of specific signaling proteins downstream the MOR. DMR signals obtained were then translated into high resolution heat maps using similarity analysis based on a numerical matrix of DMR parameters. Our data indicate that the iPOT approach clearly differentiates functional selectivity for distinct MOR signaling pathways among different opioid ligands, thus opening new avenues to discover and quantify the functional selectivity of currently used and novel opioid receptor drugs.

UR - http://www.scopus.com/inward/record.url?scp=80053928946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053928946&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0025643

DO - 10.1371/journal.pone.0025643

M3 - Article

C2 - 22003401

AN - SCOPUS:80053928946

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e25643

ER -